Navigation Links
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Date:9/5/2007

NEW YORK, Sept. 5 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and H. Lundbeck A/S of Denmark said today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 13, 2006 decision by the U.S. District Court for the District of Delaware which determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro(R), is valid and upheld the injunction preventing Ivax/Teva's proposed generic product launch, thereby confirming Forest's and Lundbeck's patent rights for Lexapro(R), which expire in March 2012.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

The patent at issue in the U.S. lawsuit is Lexapro's patent (U.S. Patent No. Re 34,712), which is set to expire in March 2012 and covers substantially pure escitalopram.

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical company dedicated to identifying, developing and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

*Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007 and quarterly report on form 10-Q for the period ended June 30, 2007.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DeForest biodiesel plant begins production
2. Biodiesel plant being built in DeForest to make alternative fuel
3. Use of X-rays to advance wood-decay knowledge leads to honor for Forest Products Lab biologist
4. Biodiversity threatened as forests become islands of green, UW professor says
5. BioRobot MDx standardize your automated protocols in clinical laboratories
6. Distance-Learning Remote Laboratories using LabVIEW
7. States are the best laboratories for healthcare reform
8. Scientific Protein Laboratories Acquired by New York firm
9. Speaker announces business members of IT Task Force
10. Doyle announces technology tax credits for Berbee
11. Doyle announces new energy, global warming policies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels (TCA) ... to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. ... one of ACA’s member angel groups. It is the highest honor available for an ...
(Date:5/18/2016)... May 18, 2016 The Biotech industry ... not mean that there are no opportunities ahead. Today, ActiveWallSt.com ... (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... and Ophthotech Corp. (NASDAQ: OPHT ). Sign up ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, ... result of asthma complications.* Costing more than $56 billion in direct costs annually, ... , “For too many, the suffering associated with uncontrolled asthma can be overwhelmingly ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):